Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Abstract

International audienceThe aim of the present study was to address the economic cost of the innovative comprehensive approach involving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat peritoneal surface malignancies, and to compare it with the financial support received by our centre

Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study

“…This approach to treatment has proven effective for patients suffering from colorectal cancer with peritoneal carcinomatosis, peritoneal pseudomyxoma and peritoneal mesothelioma, which accounts for its inclusion in the national standards of some EU countries [1,2]. However, evidence for the use of combined therapy based on HIPEC for gastric cancer (GC) still remains limited to the clinical experience of separate clinics in Japan and Europe, therefore the issue of advisability and effectiveness of HIPEC in the treatment of GC patients remains unanswered [3][4][5].…”

Peritonectomy and hyperthermic intraperitoneal chemotherapy: Cost analysis and sustainability

“…The mean cost of hospital stay was V 39,358. In another important cost analysis, 8 Baratti and colleagues arrived at a similar result, with a mean cost of one hospital stay of V 36,015.…”

“…Furthermore, two comparative surgical studies have demonstrated the superiority of CRS þ HIPEC over conventional treatment. 8,9 In the only randomized trial carried out so far, the median survival was 23 months with the combined approach and 12.6 months with fluorouracil/ leucovorin-based systemic chemotherapy. 4 In a recent retrospective controlled study by Elias and coworkers, patients with isolated, resectable peritoneal carcinomatosis had a median survival of 24 months with modern chemotherapies, but CRS þ HIPEC was able to prolong the median survival to 63 months, with a fiveyear survival rate of 51% (P < 0.05).…”

Peritoneal Mesothelioma

“…In our institutional experience, postoperative quality of life (QoL) was satisfactory, related morbidity and mortality acceptable, and financial cost-effectiveness reasonable [35,36].…”